These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27056322)

  • 1. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
    VanderVeen N; Raja N; Yi E; Appelman H; Ng P; Palmer D; Zamler D; Dzaman M; Lowenstein PR; Castro MG
    Hum Gene Ther Methods; 2016 Jun; 27(3):98-111. PubMed ID: 27056322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.
    VanderVeen N; Paran C; Krasinkiewicz J; Zhao L; Palmer D; Hervey-Jumper S; Ng P; Lowenstein PR; Castro MG
    Hum Gene Ther Clin Dev; 2013 Sep; 24(3):116-26. PubMed ID: 24007469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.
    Puntel M; Muhammad AK; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Bondale NS; Lerner J; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
    J Virol; 2010 Jun; 84(12):6007-17. PubMed ID: 20375153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.
    Muhammad AK; Puntel M; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Lawrence K; Bondale NS; Lerner J; Baker GJ; Foulad D; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
    Clin Pharmacol Ther; 2010 Aug; 88(2):204-13. PubMed ID: 20164833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AK; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-90. PubMed ID: 18283279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.
    VanderVeen N; Paran C; Appelhans A; Krasinkiewicz J; Lemons R; Appelman H; Doherty R; Palmer D; Ng P; Lowenstein PR; Castro MG
    Mol Ther Methods Clin Dev; 2014 Feb; 1():10-. PubMed ID: 25068145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
    Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.
    Candolfi M; Pluhar GE; Kroeger K; Puntel M; Curtin J; Barcia C; Muhammad AK; Xiong W; Liu C; Mondkar S; Kuoy W; Kang T; McNeil EA; Freese AB; Ohlfest JR; Moore P; Palmer D; Ng P; Young JD; Lowenstein PR; Castro MG
    Neuro Oncol; 2007 Jul; 9(3):245-58. PubMed ID: 17522335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
    Candolfi M; King GD; Yagiz K; Curtin JF; Mineharu Y; Muhammad AK; Foulad D; Kroeger KM; Barnett N; Josien R; Lowenstein PR; Castro MG
    Neoplasia; 2012 Aug; 14(8):757-70. PubMed ID: 22952428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
    King GD; Muhammad AK; Curtin JF; Barcia C; Puntel M; Liu C; Honig SB; Candolfi M; Mondkar S; Lowenstein PR; Castro MG
    Neuro Oncol; 2008 Feb; 10(1):19-31. PubMed ID: 18079358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
    Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
    Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
    King GD; Muhammad AK; Larocque D; Kelson KR; Xiong W; Liu C; Sanderson NS; Kroeger KM; Castro MG; Lowenstein PR
    Mol Ther; 2011 Oct; 19(10):1793-801. PubMed ID: 21505426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.
    Mineharu Y; Kamran N; Lowenstein PR; Castro MG
    Mol Cancer Ther; 2014 Dec; 13(12):3024-36. PubMed ID: 25256739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
    Kawashita Y; Deb NJ; Garg M; Kabarriti R; Alfieri A; Takahashi M; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):191-200. PubMed ID: 24972258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.
    Puntel M; A K M GM; Farrokhi C; Vanderveen N; Paran C; Appelhans A; Kroeger KM; Salem A; Lacayo L; Pechnick RN; Kelson KR; Kaur S; Kennedy S; Palmer D; Ng P; Liu C; Krasinkiewicz J; Lowenstein PR; Castro MG
    Toxicol Appl Pharmacol; 2013 May; 268(3):318-30. PubMed ID: 23403069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
    Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
    Curtin JF; Liu N; Candolfi M; Xiong W; Assi H; Yagiz K; Edwards MR; Michelsen KS; Kroeger KM; Liu C; Muhammad AK; Clark MC; Arditi M; Comin-Anduix B; Ribas A; Lowenstein PR; Castro MG
    PLoS Med; 2009 Jan; 6(1):e10. PubMed ID: 19143470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma.
    Hossain JA; Latif MA; Ystaas LAR; Ninzima S; Riecken K; Muller A; Azuaje F; Joseph JV; Talasila KM; Ghimire J; Fehse B; Bjerkvig R; Miletic H
    Neuro Oncol; 2019 Jul; 21(7):890-900. PubMed ID: 30958558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.
    King GD; Muhammad AK; Xiong W; Kroeger KM; Puntel M; Larocque D; Palmer D; Ng P; Lowenstein PR; Castro MG
    J Virol; 2008 May; 82(9):4680-4. PubMed ID: 18287240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoviral-mediated gene transfer into the canine brain in vivo.
    Candolfi M; Kroeger KM; Pluhar GE; Bergeron J; Puntel M; Curtin JF; McNiel EA; Freese AB; Ohlfest JR; Moore P; Lowenstein PR; Castro MG
    Neurosurgery; 2007 Jan; 60(1):167-77; discussion 178. PubMed ID: 17228266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.